Heaviest burden born by regions with high sociodemographic index, apart from Japan, which had declining trends
MONDAY, June 16, 2025 (HealthDay News) — The incidence rate of rheumatoid arthritis (RA) increased globally from 1990 to 2021, with the heaviest burden born by regions with a high sociodemographic index (SDI), according to a study published online June 16 in the Annals of the Rheumatic Diseases.
Wenyi Jin, M.D., from the Renmin Hospital of Wuhan University in China, and colleagues examined the burden of RA across 953 locations worldwide to assess socioeconomic-driven distributions and inequalities in burden. To forecast long-term burdens with scenario simulations, a deep-learning pipeline was developed.
The researchers found that RA affected 17.9 million people globally in 2021, with an increase of 13.2 percent in the incidence rate from 1990 to 2021, trending younger and broader. From 1980 to 2021, there was a 32.7 percent decrease in the age-standardized death rate, while from 1990 to 2021, global disability-adjusted life years (DALYs) nearly doubled. The heaviest burden was born by regions with a high SDI; from 1990 to 2021, regional inequalities aggregated. Declining trends were uniquely seen in Japan (1990 to 2021), exemplified by a 22.4 percent decrease in Tokyo”s age-standardized DALY rate since 1990, unlike that in other high SDI regions. Among male patients in high-smoking regions like China, implementing smoking control policies is forecasted to reduce RA-related deaths by 16.8 percent and DALYs by 20.6 percent.
“Japan”s sustained decline in DALYs despite a high SDI proves that socioeconomic status alone doesn”t dictate outcomes; proactive health care policies such as early diagnosis programs can reverse trends,” co-lead author Baozhen Huang, Ph.D., from the City University of Hong Kong, said in a statement.
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Consensus Statements Developed for Rheumatoid Arthritis-Linked Interstitial Lung Disease
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine